-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0712, an oral small molecule degrader with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.
Share
Listen to the news
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0712, an oral small molecule degrader with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has received a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending